Skip to content

Development of an Informed Consent Statement Which Communicates the Risk of Adverse Events Associated With Dry Needling

Development of an Informed Consent Statement Which Communicates the Risk of Adverse Events Associated With Dry Needling Using an Online Nominal Group

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05560100
Acronym
DNICNGT
Enrollment
5
Registered
2022-09-29
Start date
2022-09-19
Completion date
2022-10-31
Last updated
2023-06-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Dry Needling

Keywords

informed consent, adverse event, nominal group technique

Brief summary

As Dry Needling (DN) continues to see increased use in the clinic, there is a need to establish adverse events that could occur as a result of DN intervention. The adverse events are important to consider when an individual needs to make an informed decision regarding their care. It is important to consider how such information should be presented during the informed consent process to improve an individual's ability to make a sound decision regarding their own personal care.

Detailed description

Dry Needling (DN) has been defined by a Task Force organized by the Federation of State Boards of Physical Therapy (FSBPT) as a skilled intervention performed by a physical therapist using filiform needles to penetrate the skin and/or underlying tissues to affect change in body structures and functions for the evaluation and management of neuromusculoskeletal conditions, pain, movement impairments, and disability. As DN interest continues to expand and studies continue to show the feasibility of applying DN to a wider range of pathological conditions, there is a need to understand the risks related to the use of DN. Understanding the risks associated with DN will allow for improvements in clinical decision making regarding it's application in the clinic. Enhancing patient choice is a central theme of medical ethics and law. Informed consent (IC) is the legal process used to promote patient autonomy while concepts of shared decision making (SDM) is a widely promoted ethical approach. IC is a means of respecting the autonomous preferences of persons seeking health care or participation in research. Empowerment of the patient is important in healthcare and can lead to improvements in overall quality of patient care and outcomes. To date, there has been little research conducted that explored the topic of how risks should be presented during the IC process. The purpose of this study will be to utilize expert consensus to establish a risk statement for adverse events associated with DN that an be used during IC.

Interventions

OTHERNominal Group Technique - 2 to 3 hour virtual meeting

Participants will be invited to a 2-3 online virtual online meeting with the goal of constructing and defining elements for producing a risk statement for dry needling that can be used for informed consent.

Sponsors

Youngstown State University
Lead SponsorOTHER

Study design

Observational model
OTHER
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to 100 Years
Healthy volunteers
Yes

Inclusion criteria

Participants must be 18 years old or above and be able to read/write in English Participants must provide informed consent Participants must meet the criteria of one of the previously defined cohort groups used in the study Dry Needling Experts (1) Must have \>= 5 years of clinical practice performing dry needling and at least ONE of the following secondary criteria: 1. Certification in Dry Needling 2. Completion of a manual therapy fellowship that included dry needling training 3. \>= 1 total scholarly product (poster presentation, author of a peer-reviewed publication) involving the use of dry needling Legal Expert An individual who is an attorney and who has had training in health law as evidenced by at least ONE of the following criteria: 1. Training in health law as evidenced by ONE of the following: 1. Concentration/Certification in Health Law 2. L.L.M in health or medical law 3. SJD in health law 2. Experience in litigating medical malpractice cases involving failure to obtain informed consent 3. Published scholarship on informed consent in an academic journal (\>= 1) Policy Expert An individual who has a degree in bioethics with at least ONE of the following criteria: 1. \>= 5 years of experience in obtaining informed consent or an advanced graduate degree in bioethics 2. Has served on ethics related committee in a healthcare institution or healthcare society/professional association 3. Is or has been a member of a state licensing board Patient Must have participated in \>= 1 session of dry needling treatment and not be a healthcare provider

Exclusion criteria

Participants who did not provide informed consent Participants who did not meet the inclusion criteria of one of the four cohort groups defined in the study.

Design outcomes

Primary

MeasureTime frameDescription
Demographic Information FormUp to 2 hoursContains questions about the characteristics of the participants
Ranking of StatementsA 2 hour virtual meeting for participants to rank statementsParticipants will rank statements generated during the meeting to determine which statement best meets consensus within the group

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 11, 2026